Shilpa Medicare’s JV Oncosol and partner Shorla Oncology gets US FDA approval for IMKELDI

Shilpa Medicare's Joint Venture Oncosol, along with its partner Shorla Oncology, on Wednesday announced that the US FDA has approved IMKELDI (imatinib oral solution).

IMKELDI is the first oral liquid form of imatinib used to treat certain forms of leukemia and other cancers.



IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy. IMKELDI can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).

Shares of Shilpa Medicare Ltd. ended 1.06% higher at ₹897.80 today. The stock has rallied 180% so far in 2024.